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takes place in two compartments: the lamina propria and 
the epithelium. While lamina propria CD4 T cells have 
a recognized role in the pathogenesis of  CD, the role of  
CD8 T cells in the intestinal epithelium is controversial[5].
CD is characterized by intestinal malabsorption and 
subtotal or total atrophy of  intestinal villi which improves 
after gluten-free diet (GFD)[6]. The classic form of  CD 
presents several symptoms such as diarrhea, abdominal 
pain, weight loss and nutritional defi ciencies, particularly 
of  iron, folate, calcium, and vitamin D[7]. However, there 
is a large variety of  clinical presentations characterized by 
the presence of  extra-intestinal manifestations, including 
anemia[8], persistent hypertransaminasemia[9], osteopenia[10], 
neurological[11], psychiatric and affective disorders[12-14], 
features of  hyposplenism (Howell-Jolly bodies and 
thrombocytosis)[15] and autoimmune diseases[6]. In the last 
years, growing evidence has documented the involvement 
of  skin diseases among the extra-intestinal manifestations 
of  CD[17]. The aim of  this review is to report all CD 
associated skin manifestations described in the English 
literature and to analyze the possible mechanisms involved 
in this association.
Dermatitis herpetiformis
Dermatitis herpetiformis (DH) is a well-described entity, 
presenting as an itchy, chronic, papulovesicular eruption 
which may leave pigmentation and scarring[18]. Classically, 
skin lesions are characterized by a symmetrical eruption 
on the extensor surfaces of  the body such as the knees, 
elbows, buttocks, and back. DH tends to occur more in 
the adult male (M/F ratio 2:1) who may also present with 
the involvement of  oral and genital membranes. However 
this pattern is reversed in children who may simply have 
purpura over the palmar surfaces. The age of  onset varies 
with geographical location and the incidence is highest 
in Ireland and Sweden and rare in Asia[19]. Histology 
of  lesional skin shows micro abscesses consisting of  
neutrophils and eosinophils within the dermal papillae. 
Sub-epidermal vesicles and bullae are produced within 
the lamina lucida as a result of  collagen degradation. 
Furthermore there is an increased number of  activated 
T cells. Direct immunofluorescence of  the normal 
skin shows the pathogenomic granular IgA deposits in 
the papillary dermis but the exact target antigen is still 
unknown[19-21]. These deposits are often associated with C3 
to support the suggestion that the complement is activated 
via the alternative pathway and C5[22,23]. The activated 
fraction, C5a, is highly chemotactic for neutrophils and 
may contribute to the infl ammatory change at the papillary 
tip.
HLA studies in patients, who have DH based on 
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Abstract
Celiac disease (CD) is an autoimmune gluten-dependent 
enteropathy characterized by atrophy of intestinal 
villi that improves after gluten-free diet (GFD). CD is 
often associated with extra-intestinal manifestations; 
among them, several skin diseases are described in CD 
patients. The present review reports all CD-associated 
skin manifestations described in the literature and tries 
to analyze the possible mechanisms involved in this 
association. The opportunity to evaluate the possible 
presence of CD in patients affected by skin disorders is 
discussed.
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INTRODUCTION
Celiac disease (CD) can be defi ned as a chronic immune-
mediated gluten-dependent enteropathy, resulting from 
an inappropriate T-cell-mediated immune response, 
against ingested gluten in genetically predisposed people[1]. 
Epidemiological studies have shown that CD is very 
common and affects about 1 in 250 people[2]. CD is a 
multigenic disorder associated with HLA-DQ2 (DQA1*/
DQB1*2) expressed in more than 90% of  patients, or 
HLA-DQ8 (DQA1*0301/DQB1*0302)[3]. The expression 
of  these molecules is necessary, but not sufficient, to 
develop the disease[4]. The immune response to gluten 
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clinical and immunological criteria, have shown that 
85-90% are HLA B8-positive and that there is an even 
stronger associat ion with HLA DW3 and DRW3. 
Interestingly, patients with a GSE without DH show a 
similar high incidence of  these antigens[24]. Specifi c B cell/
macrophage antigens have been noted in patients with DH 
and the gluten-sensitive enteropathy[25]. Family studies have 
shown that these B cell antigens segregated independently 
of  HLA antigens[26]. One hypothesis is that both HLA and 
non-HLA disease genes are necessary for the development 
of  lymphoid cell surface receptors that recognize gluten.
Antigluten, antiendomysium, antigliadin and tissue 
transglutaminase antibodies have been detected in patients 
with DH[27-29]. These gluten-specific cells migrate to 
the gut mucosa where they mediate cytotoxic reactions 
involving the epithelial cells[30]. There is an immunogenetic 
association with HLA DR3 DQW2 (HLA class II alleles 
DQAI 0501 and DQBI 0201), which is very much more 
common in Caucasians than in Orientals and may be 
important for the different incidences of  DH in different 
ethnic populations. Gluten must be present in the diet for 
the development of  DH; however, a genetic susceptibility 
to gluten has been proposed as an etiological mechanism. 
This observation could explain why DH is very common 
in some Asian populations, which have a low daily gluten 
intake (e.g., 7-8 g/d in Korea) compared with Western 
populations which have higher daily gluten intake (e.g., 
15-20 g/d in Scandinavia)[19].
As CD and DH may seem to be vastly different, they 
both share a unique intestinal sensitivity to gluten, with 
the rash of  DH thought to be an external marker of  the 
underlying intestinal sensitivity that is likely to be the result 
of  molecular mimicry between the auto antigen tissue 
transglutaminase resident in the gut and the skin derived 
epidermal transglutaminase.
Although patients with DH are unlikely to have 
gastrointestinal symptoms or features of  malabsorption, 
they have small intestinal histopathologic changes, with 
either a classical atrophic appearance with complete villous 
atrophy, or more commonly a more subtle infiltrative 
pattern with partial or no villous atrophy. When there is a 
suspicion of  DH with a negative skin biopsy but serologic 
evidence of  CD, a skin biopsy should be repeated 
given the patchy nature of  the lesions, and referral to 
a gastroenterologist for small bowel biopsy should be 
pursued. Interestingly, topical skin application of  gluten-
containing products does not produce the rash of  DH in 
susceptible patients; however, oral or rectal introduction of  
gluten has been found to result in the classic DH rash[31,32].
The DH rash is often treated with dapsone in 
conjunction with the gluten withdrawal. In addition 
to improving the histological changes of  the small 
intestine, the gluten-free diet may also allow a reduction 
of  suppressive medication[32]. Just as patients with CD 
are at a higher risk of  malignancies such as lymphomas, 
so are those patients with DH not compliant with GFD, 
which should motivate patients with DH to follow the diet 
regardless of  the absence of  other symptoms[31].
Linear IgA bullous dermatosis
Linear IgA bullous dermatosis (LABD) is a rare disease 
characterized by erythematous papules or groups of  
small vesicles. The onset may be acute or gradual and the 
predominant symptom is usually pruritus. Immunoelectron 
microscopic studies have shown a linear deposition of  
IgA along the lamina lucida or in the sub-basal lamina 
area of  stratifi ed squamous epithelium[32]. At the moment, 
it is considered as a distinct entity from DH and Bullous 
pemphigoid[32,33]. The incidence of  gluten sensitivity 
enteropathy (GSE) in LABD has been described in 
the literature to range from 0% to 24%[33-36]. The HLA 
haplotype (A1, B8, DR3) of  LABD patients is often that 
found in classic DH which is in >85% of  CD patients[37,38]. 
Although the prevalence of  CD is low in LABD, some 
authors have suggested a diagnosis of  GSE in these 
patients[34-36,39].
Urticaria
Urticaria is an eruption of  transient erythematous or 
edematous swellings of  the dermis or sub-cutaneous 
tissue and is due to a local increase of  permeability of  
capillaries and small venules. Hautekeete et al [40] first 
described the association between CD and chronic 
urticaria, although this association is still debated[41]. 
Adults with CD also often have an increase of  atopic 
or immunologic disorders[42,43]. Scala et al reported that 
a GFD eliminated both skin and intestinal symptoms in 
patients with concomitant CD and chronic urticaria[44]. 
The passage of  antigens and immune-complex formation 
may be facilitated by an increased mucosal permeability. 
Theoretically, this mechanism might cause urticarial lesions 
and so, by restoring the integrity of  the mucosa, a gluten-
free diet might resolve skin symptomatology.
Hereditary angioneurotic edema
Hereditary angioneurotic edema (HANE) is characterized 
by recurrent edematous attacks in the sub-cutis and 
sub-mucous due to C1-esterase inhibitor (C1-INH) 
deficiency[45]. Brickman et al [46,47] described HANE in 
association with inflammatory bowel diseases (IBD). 
In 2002, Farkas et al[48] first described the simultaneous 
occurrence of  HANE and CD. The classic activation 
pathway of  the complement system plays a potential role 
in the immune regulation of  both disorders: it is defi cient 
in HANE and gluten is a potent activator of  the alternative 
pathway in CD[49]. There might also be a genetically 
determined etiology of  both diseases[50]. Complement 
testing is justified whenever the GI symptoms of  CD 
persist despite restoration of  damaged mucous. Conversely 
HANE unresponsive to adequate prophylaxis should 
prompt for complete GI group tests[48].
Cutaneous vasculitis
CD may give rise to many skin manifestations but vascu-
litic skin lesions have rarely been encountered[51,52]. Leu-
cocytoclastic vasculitis is characterized by the involvement 
of  postcapillary venules. The skin is the most common 
organ involved with the usual clinical appearance of  a pal-
pable purpura. In most cases, leucocytoclastic vasculitis is 
mediated by immunocomplex deposition and the antigen 
being either exogenous or endogenous[53]. The coexistence 
of  cutaneous vasculitis and CD might be related to in-
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creased intestinal permeability[54], and immune complexes, 
originating from exogenous or endogenous antigens, mi-
ght circulate because of  the impaired phagocytic function 
of  reticular endothelium system and be deposited in the 
skin[55]. As in inflammatory bowel disease (IBD), exoge-
nous antigens may permeate the damaged CD mucous in 
larger quantities than normal[54,56]. This is refl ected by signi-
fi cant serum milk and gluten fraction antibody titers[57,58]. 
Alternatively, an autoimmune sensitization may result be-
cause of  the release of  endogenous antigens from dama-
ged small bowel mucosa[59]. Meyers et al[60] described a case 
of  cutaneous vasculitis complicating CD and the remis-
sion of  skin lesions after the treatment with a strict GFD. 
Treatment of  leucocytoclastic vasculitis has generally been 
diffi cult, but corticosteroids and a gluten-free diet may im-
prove the dermatosis in cases associated with CD[52].
Erythema nodosum
Erythema nodosum (EN) is a chronic panniculitis 
characterized by inflammation of  the fat septa and its 
etiology seems to involve an allergic or immune complex-
mediated reaction to many antigens. Triggers include 
infections, sarcoidosis, adverse drug reaction, IBD, and 
lymphomas[61]. EN generally resolves in 5-8 weeks but if  
antigenic stimulus persists, the disease may last for a long 
period[62]. In 1991, Durand et al first observed a causal 
linkage between CD and EN[63]. CD can be a triggering 
factor of  EN because an altered intestinal permeability 
to endogenous or exogenous antigens may provoke the 
immunologic response. EN is also a common fi nding in 
sarcoidosis which frequently coincides with CD[62-65]. When 
EN skin lesions are chronically recurrent or persistent, it 
is advisable to search for an underlying CD even if  it is 
diffi cult to estimate the true incidence of  the coexistence 
of  both diseases.
Erythema elevatum diutinum
Erythema elevatum diutinum (EED) is a rare variation of  
cutaneous leucocytoclastic vasculitis, originally described 
in 1894[66]. Its lesions appear as soft erythematous papule-
plaques and become hard nodules mainly symmetrically 
affecting the backs of  the hands and other extensor 
surfaces overlying the joints[67]. Ulceration, arthralgia and 
pain can be other features of  this disease[67,68]. Even if  it is 
presumed to be an immune reaction by bacterial antigens, 
the etiology of  EED is unknown[69]. EED has been 
described in association with several other immunological 
diseases, especially paraproteinemias (i.e., monoclonal 
IgA gammopathy)[70]. Tasanen et al[70] detected dermo-
epidermal IgA and complement deposits in lesional skin 
of  a patient affected by CD; the histopathology was 
suggestive of  EED[71]. The EED skin lesions appear to 
result from an immune complex reaction, as suggested 
by the association of  various infections or autoimmune 
diseases. Joint pains are often present in patients affected 
by autoimmune disease such as EED but are also often 
found in association with CD[72]. Some authors have 
therefore suggested that it is important to warrant 
consideration of  underlying CD in at least some patients 
with EED[71-73].
Necrolytic migratory erythema
The features of  necrolytic migratory erythema (NME) 
have been reviewed by several authors. Becker et al[74] 
fi rst described a cutaneous reaction pattern with specifi c 
histopathologic features in association with a pancreatic 
islet cell carcinoma. NME is a term used by Wilkinson[75] 
to describe the characteristic skin disease related with 
glucagonoma. Typically lesions start with figurate areas 
of  erythema followed by erosions mainly over the trunk, 
perineum, lower extremities and perioral area. Eventual 
shedding is caused by superfi cial necrosis[76]. Most patients 
have angular cheilitis, stomatitis, glossitis, diffuse alopecia 
and brittle nails. Gastrointestinal symptoms such as weight 
loss and diarrhea are common[77]. Most cases of  NME 
were part of  the glucagonoma syndrome[76-77]. NME oc-
casionally occurs with chronic liver disease or malabsorp-
tion with villous atrophy[78,79]. Kelly et al[80], Goodenberg 
et al[79] and Thorisdottir et al[81] described the association be-
tween CD and NME. The etiology of  NME is uncertain, 
although deficiencies of  zinc, amino acids, or essentially 
fatty acids could play an important role[77,78,82,83]. It must be 
stressed that in CD patients with NME, this latter disorder 
seems to have an excellent response to GFD[79,81].
Psoriasis
Psoriasis is a chronic, relapsing dermatosis characterized 
by scaling, erythema, and less commonly pustulation[84]. It 
has been demonstrated that psoriasis is an immunological 
disease with hyperproliferation of  T-cell mediated 
keratocytes[85]. Recent data indicate that HLA-Cw*0602 
may play an important pathogenetic role in the majority 
of  psoriasis patients[86]. Immune mechanisms have an 
important role in the pathogenesis of  this disease. In 
particular, an overexpression of  T helper cell type 1 (Th1) 
cytokines and a relative under-expression of  Th 2 cytokines 
have been shown in psoriatic patients[87]. The treatment 
is often diffi cult; all currently available effective remedies 
are retinoids or immunosuppressant drugs such as 
steroids or cyclosporin[84], other than topical treatment[88], 
photochemotherapy (PUVA)[89] and biological treatment 
such as infliximab or etanercept[90]. Recent studies have 
showed an association between CD and psoriasis[91,92,93] 
and an improvement of  skin lesions after 3-6 mo of  
GFD, without other pharmacological approaches, was 
described[91]. However at present the relationship between 
CD and psoriasis remains controversial since there are 
few data on this topic and other authors sustain that this 
association seems to be coincidental[94]. 
In one study, 10 out of  32 (31%) subjects affected 
by different clinical forms of  psoriasis had positive 
antireticulin antibodies with a variability of  titers, related 
to the extent of  the disease[95]. Subsequently, in a first 
screening study conducted by Michaelsson et al[96] 16% of  
302 subjects with psoriasis had IgA and/or IgG AGA. 
Only in 1 of  11 IgA AGA-positive patients from this 
group screened for antibodies to reticulin/EMA was 
this positive. An increase of  EG2-positive eosinophils in 
duodenal mucosa associated with elevated serum levels of  
eosinophil cation protein (ECP) has been documented in 
psoriatic subjects with AGA, but no tendency to higher 
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ECP values has been detected in those with AGA[97]. The 
same authors reported that the increase in the number 
of  eosinophils in the gastrointestinal tract is explained as 
being part of  some unknown process that may be related 
to the development of  skin psoriatic lesions. Cardinali and 
co-workers[92] performed a study to verify whether gluten 
intolerance is more frequent in Mediterranean subjects 
with psoriasis than in healthy controls. The sera of  39 
psoriatic patients and 39 controls were screened for AGA, 
EMA, antibodies anti-transglutaminase (TgA), ECP, serum 
total IgE levels and number of  eosinophils. The results 
showed positivity for IgG AGA in two psoriatic patients, 
one borderline for TgA, and none was positive for EMA 
or IgA AGA. In these subjects the authors found high 
serum levels of  ECP and IgE, but a normal number of  
eosinophils; on the contrary eosinophil count and serum 
IgE levels were within the normal range in the controls. 
Michaelsson et al[91] evaluated the effect of  GFD in 33 
AGA positive patients and six AGA negative patients 
with psoriasis in an open study. Of  the 33 AGA-positive 
patients, 2 had IgA EMA, and at the duodenal biopsy 
15 showed an increased number of  lymphocytes in the 
epithelium, but in some this increase was only slight. GFD 
was for 3 mo. Thirty out of  thirty-three patients strictly 
complied with GFD, after which they showed a signifi cant 
decrease of  psoriatic lesions. This included a significant 
decrease in the 16 AGA positive patients with normal 
routine histology in duodenal biopsy. The AGA negative 
patients did not improve. There was also a significant 
decrease in the serum of  eosinophil cation protein in 
patients with elevated AGA. In conclusion, the positive 
effects of  GFD were observed not only in patients with 
an increased number of  lymphocytes in the duodenal 
epithelium, but also in some patients with seemingly 
normal epithelium[91,98].
Our group recently reported a case of  severe psoriasis 
in a CD patient, not responding to specifi c therapies for 
psoriasis and in whom the regression of  skin lesions 
after GFD was very rapid[99,100]. The association between 
psoriasis and CD was subsequently confirmed by Ojetti 
et al[101]. The authors evaluated the prevalence of  CD in 
patients affected by psoriasis, showing a high frequency of  
CD (4.34%) in psoriatic patients.
At present the mechanisms implicated in the possible 
association between CD and psoriasis, and the effect of  
GFD on psoriatic skin lesions are not known. There are 
some hypotheses:
Hypothesis 1: Abnormal small intestinal permeability, fre-
quently present both in psoriasis[102] and  in CD patients[103], 
could be a triggering factor between CD and psoriasis.
Hypothesis 2: T cells play an important role in the 
pathogenesis of  both psoriasis and CD. An increased 
number of  T cells in the blood, in the dermis and in the 
epidermis of  psoriatic patients has been documented[87]. In 
CD patients, gliadin induces a sensitization of  T cells[104] 
and this may play a role in the pathogenesis of  psoriatic 
skin lesions[99].
Hypothesis 3: Psoriatic lesions in CD patients could be 
related to vitamin D defi ciency, which is present both in 
CD[105] and in psoriasis[106-107].
Vitiligo disease
Vitiligo is a specific, common, often heritable acquired 
disorder characterized by well-circumscribed milky white 
cutaneous macules devoid of  identifi able melanocytes[108]. 
This disease appears to be more commonly observed in 
parts of  the body exposed to the sun and in darker skin 
types and may develop at any age. The etiology is complex: 
there appears to be a certain genetic predisposition and a 
number of  potential precipitating causes (i.e. crisis, illness, 
physical injury, etc.). Numerous attempts to identify HLA 
markers have revealed certain ethnic-specific markers: 
HLA-DR4 (blacks), B13 (Jews) and BW-35 (Yemenites). 
Theiligore[108] has proposed three prevailing theories to 
explain vitiligo: the neural hypothesis, the self-destruct 
hypothesis and the immune hypothesis. It carries a risk for 
ocular abnormalities, particularly iritis, and a significant 
risk for thyroid disease, diabetes mellitus, Addison’s disease 
and pernicious anemia.
The re l a t ionsh ip be tween CD and v i t i l i g o i s 
controversial. Although some authors have described 
some cases of  vitiligo in patients affected by CD[109,110], 
a serological screening study for CD in patients with 
vitiligo did not show any correlation between these two 
immunological disorders[111]. This implies that the sporadic 
associated cases must be considered as coincidental.
Behçet’s disease
A history of  oral ulceration has been described in 25% 
of  patients with CD and about 2-4% of  patients with 
recurrent oral ulceration also have CD[112]. Behçet’s 
disease (BD) is characterized by recurrent ulceration of  
the mouth and genitalia associated with iritis. Males are 
affected 5-10 times more frequently than females and 
the onset is usually between the ages of  10 and 30. The 
oral ulcers usually show only non-specific inflammatory 
changes, although there may be infi ltration of  the grossly 
thickened walls of  thrombosed arterioles. Some authors 
have suggested that BD may be caused by a virus[113] and 
antibodies against mucous membrane were demonstrated 
in 17 of  40 patients[114] but their signifi cance has not yet 
been evaluated. Triolo and co-workers[115] described 3 
cases of  coexistence of  BD and symptomless CD in 11 
patients with BD (defi ned according to International Study 
Group-ISG criteria). IgA and IgG class AGA and EMA 
were found in one patient, another two had IgG AGA 
alone. There is suggestive but as yet inconclusive evidence 
of  a probable association between CD and autoimmune 
diseases such as BD. It could be supposed that both 
diseases are likely the result of  molecular mimicry between 
two undefined auto antigens or virus trigger action. In 
patients affected by BD, it may therefore be important to 
search for underlying undiagnosed CD, but future studies 
are needed to shed light on this point.
Oral lichen planus
The associat ions between CD and recur rent oral 
ulceration, glossitis, angular cheilitis and burning mouth 
are common[112]. Three to six percent of  patients with 
these oral manifestations may have underlying undiagnosed 
CD[112,116]. Fortune et al [117] described the erosive type 
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of  oral lichen planus (OLP) in a patient with gluten 
enteropathy. OLP is not rare and frequently involves the 
buccal mucosa, gingiva and tongue. In both the diseases, 
the lesions had a mucosal T-cell infiltrate and the relief  
from eating a gluten-free diet was surprising. It is not 
clear whether the oral lesions are a direct manifestation of  
CD or due to the effect of  malabsorption on the rapidly 
dividing mucosal cells already predisposed to soreness 
by a pre-existing disease; because palliative medication 
of  chronic ulcerative stomatitis is often ineffective, it is 
important to detect the underlying nutritional defi ciencies 
for the patient’s general well-being also.
Dermatomyositis
Dermatomyositis is a disorder mainly of  the skin, muscle 
and blood vessels in which characteristic erythematous 
and edematous changes in the skin are associated with 
muscle weakness and inflammation. An underlying 
carcinoma is commonly described in adults. Juvenile 
dermatomyositis (JDM) has a more favorable prognosis 
for life but functional disability is usually severe. Its 
pathogenesis is probably due to cell-mediated immunity to 
muscle antigens, humoral immunity and immune complex 
deposition[118].
Some authors have described an association with 
CD[119-122]. Both diseases have a strong association with 
DQA1 0501 heterodimer because a linkage disequilibrium 
with HLA-DR3 haplotype or alternatively DR5/DR7 
heterozygosity in CD[123,124] DQA1 0501 may lead to the 
activation of  CD4-positive T cells by presentation of  a still 
unidentifi ed peptide that may induce CD or JDM. Evron 
e t al [125] and Marie e t al [121] have also described the 
assoc ia t ion between der matomyos i t i s (DM) and 
polymyositis (PM) and CD in adults. For these authors CD 
may be included within the spectrum of  gastrointestinal 
manifestations of  DM/PM and they showed that GFD 
may resolve clinical and laboratory abnormalities.
Porphyria
Mustajoki et al [126] and subsequently Twaddle et al [127] 
reported the coincidental diagnosis of  CD in porphyrics. 
Patients with CD and porphyria present particular 
problems in terms of  management[128]. The porphyrias 
are a group of  rare diseases affecting the enzymes of  the 
heme biosynthetic pathway with subsequent accumulation 
of  porphyrins in the tissues. These substances are 
photosensitizers and their accumulation in the skin 
can cause bullae, erosions, increased fragility, scarring, 
hirsutism and pigmentation on photo-exposed areas. CD 
is often associated with DH which has some features in 
common with skin lesions of  porphyrias. In one type 
of  porphyria, variegate porphyria (VP), accumulation 
of  porphobil inogen and 5-aminolevul inic acid is 
associated with gastrointestinal symptoms and an acute 
neuropsychiatric syndrome. Some drugs such as dapsone 
are precipitants of  these acute attacks[128]. It is essential 
that patients with bullous skin lesions are adequately 
investigated to distinguish VP from DH because the 
administration of  dapsone could have a potentially fatal 
outcome. Furthermore, symptomatic control of  CD (e.g., 
malabsorption, anorexia, calorie restriction) can prevent 
precipitation of  acute attacks of  VP and because gluten 
sensitivity itself  may be associated with neurological and 
psychiatric disorders[12,15], neuropsychiatric porphyria could 
be one of  the differential diagnoses[129].
Alopecia areata
Alopecia areata (AA) is a chronic autoimmune disease 
characterized by non-scarring alopecia. Histologically it 
is possible to find perifollicular lymphocyte infiltration, 
pointing to an immunologic etiology such as CD. In both 
the diseases there is the presence of  organ-specifi c autoa-
ntibodies[110,130-132], T-lymphocyte infi ltration at the site of  
lesion[133,134], association with HLA genes[135,136] and possible 
etiologic importance of  viral co-factors[137,138] 
In the general population the prevalence of  CD is 
1 in 305[139] and of  AA is 1 in 819[140]. Corazza and co-
workers[141] found that the prevalence of  CD in patients 
with AA was 1 in 85. Although remission and recurrence 
may be observed during the clinical course of  AA[142], many 
patients on gluten-free diet showed complete regrowth 
of  scalp and other body hair and no further recurrence 
of  AA at follow-up[141,143]. The positive effects of  gluten-
free diet on the pattern of  autoimmune conditions, 
such as AA, associated with CD have been attributed 
to a normalization of  the immune response. This study 
suggests that AA patients constitute a novel risk group of  
CD. Because AA may be the only clinical manifestation of  
CD, some authors suggest GSE serological screening tests 
in alopecia universalis[141].
Acquired hypertrichosis lanuginosa
Acquired hypertrichosis lanuginosa (AHL) is a rare disease 
and there are less than 40 cases in the literature[144,145]. This 
type of  hypertrichosis is characterized in its extreme by 
the rapid growth of  fi ne, down-like hair all over the body, 
occasionally associated with glossites and loss of  taste. A 
lesser degree of  hypertrichosis in which lanugo hair occurs 
only on the face is more common. It is three times more 
common in females than in males and most commonly 
associated with malignancy[146]. Lymphomas, carcinoid 
tumors, and the Zollinger-Ellison syndrome have also been 
associated with this pathology[146,147]. 
In 1988, Corazza et al [148] described the only case 
reported in the literature of  acquired hypertrichosis 
lanuginosa associated with CD. This case report confi rms 
the paraneoplastic features of  AHL. CD is often reported 
as being associated with tumors and can precede clinical 
presentation of  the tumors[149].
Pyoderma gangrenosum 
The pyoderma gangrenosum (PG) is a neutrophilic 
dermatosis, with destructive, necrotizing and non 
infectious ulcera, involving face and inferior limbs. The 
association between PG and CD has been described in 
some case reports and the importance of  GFD in the 
resolution of  PG has been suggested[150].
Ichthyosiform dermatoses
The ichthyosiform dermatoses consist of  a heterogeneous 
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g roup of  hered i ta r y d i sorders, a l l of  which are 
characterized by the accumulation of  large amounts of  
scale on the cutaneous surface. The earliest reports of  
ichthyosis have been traced to the Indian and Chinese 
literatures several hundred years B.C. and a dermatology 
text by Willian fi rst discussed the problem. Kinetic studies 
of  the epidermis in the major forms of  ichthyosis have 
shown increased germinative cell hyperplasia and increased 
transit rate through the epidermis in lamellar ichthyosis[151]. 
Menni et al[152] fi rst reported a case of  ichthyosis revealing 
CD but the reason for this association is still unknown.
Pellagra
Pellagra is a disease characterized by lesions of  the skin 
usually proceeded by prodromal symptoms, especially of  
digestive and nervous systems. The dermatosis begins 
as erythema and edema on the back of  the hands, with 
pruritus and burnings, determined especially by exposure 
to the sun and by localized pressure. In some patients, 
several days after the onset of  erythema, blisters appear; 
these run together to form bullae and then break. In the 
second stage, the dermatosis becomes hard and brittle. 
The skin may look like a goose. The usual sites are the 
face, neck, dorsal surfaces of  the hands, arms, and feet. 
The cause of  pellagra is still not entirely clear. It may arise 
from a diet deficient in niacin or tryptophan, or more 
commonly both, and aminoacid imbalance may also play 
a part[153]. In 1999, Schattner[153] described a case of  a man 
with a pellagra-like syndrome due to CD.
Generalized acquired cutis laxa
Cutis laxa (CL) is a heterogeneous group of  inherited and 
acquired (generalized or localized) diseases characterized 
by looseness of  the skin with the development of  inelastic 
folds that gives the affected person a prematurely senile 
appearance[154-156]. CL presents a destructive phenomenon 
of  previously apparently normal elastic fibers, with 
cephalocaudal progression[157]. It occurs mainly in adults 
and the etiology is unknown. Immunological abnormality 
has been postulated to explain the destruction of  elastic 
tissue[158]. Generalized acquired cutis laxa (GACL) has 
been reported in association with infectious disorders, 
drugs and autoimmune diseases[154,158,160-164]. Many authors 
have described a dermal deposit of  immunoglobulins 
(IgA) in various diseases, suggesting that destruction 
of  elastic tissue may be immunologically mediated[160]. 
Cases of  association between GACL and CD have been 
reported[160,165]. Bodvarsson et al[166] proposed that dietary 
intake of  glutenin may induce the production of  antibodies 
to elastin and mediate adherence of  neutrophils[167,168]. 
A cross-reaction is possible between gluten and some 
components of  elastic fibers, since glutenin presents 
a 22.3% amino acid sequence similar to elastin[166,169]. 
Garcia-Patos and co-workers[165] described a case of  
GACL associated with CD, evidence of  IgA deposits on 
the dermal elastic fibers and moderate improvement of  
eruption after treatment with GFD.
Atypical mole syndrome and congenital giant naevus
Montalto et al[170] first described the association between 
CD, atypical mole syndrome and congenital giant naevus. 
They reported a case of  a patient affected by a rare 
multiple disorder of  the cutaneous pigmentary system, 
which increased the risk of  melanoma, and by CD which 
is frequently associated with some neoplasms[171-174]. Some 
authors have therefore suggested a more careful objective 
examination in all the patients with CD[170].
CONCLUSION
CD is an enteropathy associated with various extra-
intestinal manifestations, including several skin diseases. 
Several hypotheses have been proposed regarding the 
possible mechanisms involved in this association. In 
particular, an abnormal small intestinal permeability 
appears to be implicated, which may allow the crossing of  
endogenous or exogenous antigens and may provoke the 
immunological response, common immune mechanisms, 
vascular alterations and, lastly, vitamin and aminoacid 
deficiency secondary to malabsorption in patients with 
CD. However at present the data are not homogeneous 
and most of  the evidence for the association between CD 
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and skin disorders is based on “case-reports”, making it 
diffi cult to draw defi nitive conclusions on this topic; future 
controlled studies are consequently needed to verify the 
real involvement of  the cutaneous district in CD (Table 
1). Nevertheless, despite these limitations, the opportunity 
to investigate the possible presence of  CD in some 
dermatological patients seems at present justifi ed. 
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